JP2011516501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516501A5 JP2011516501A5 JP2011503304A JP2011503304A JP2011516501A5 JP 2011516501 A5 JP2011516501 A5 JP 2011516501A5 JP 2011503304 A JP2011503304 A JP 2011503304A JP 2011503304 A JP2011503304 A JP 2011503304A JP 2011516501 A5 JP2011516501 A5 JP 2011516501A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cancer
- tumor
- ace2
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 12
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0056608A AT506632A1 (de) | 2008-04-09 | 2008-04-09 | Behandlung von tumorerkrankungen |
| ATA566/2008 | 2008-04-09 | ||
| PCT/AT2009/000136 WO2009124330A2 (de) | 2008-04-09 | 2009-04-07 | Behandlung von tumorerkrankungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516501A JP2011516501A (ja) | 2011-05-26 |
| JP2011516501A5 true JP2011516501A5 (enExample) | 2012-05-31 |
| JP5650639B2 JP5650639B2 (ja) | 2015-01-07 |
Family
ID=41130316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503304A Active JP5650639B2 (ja) | 2008-04-09 | 2009-04-07 | 腫瘍疾患の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8946162B2 (enExample) |
| EP (2) | EP2644203A1 (enExample) |
| JP (1) | JP5650639B2 (enExample) |
| AT (1) | AT506632A1 (enExample) |
| AU (1) | AU2009235931B2 (enExample) |
| CA (1) | CA2720616C (enExample) |
| DK (1) | DK2274005T3 (enExample) |
| ES (1) | ES2425308T3 (enExample) |
| NZ (1) | NZ588435A (enExample) |
| PL (1) | PL2274005T3 (enExample) |
| PT (1) | PT2274005E (enExample) |
| WO (1) | WO2009124330A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
| EA034043B1 (ru) * | 2012-06-06 | 2019-12-20 | Аттоквант Диагностикс Гмбх | Способ определения продуктов деградации пептидов из протеолитического каскада в образцах крови |
| US8557958B1 (en) | 2012-06-18 | 2013-10-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of diabetes |
| US8633158B1 (en) | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| JP2016504042A (ja) * | 2013-01-14 | 2016-02-12 | アペイロン バイオロジックス アーゲー | 改変ａｃｅ２ポリペプチド |
| EP3079684B1 (en) * | 2013-12-11 | 2019-11-13 | Alterras Therapeutics GmbH | Compositions and methods for the treatment of diseases related to the renin-angiotensin-system |
| US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
| WO2018204385A1 (en) * | 2017-05-02 | 2018-11-08 | Beth Israel Deaconess Medical Center, Inc. | Combination therapy for cancer |
| CA3082610A1 (en) * | 2017-11-29 | 2019-06-06 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| US20230181759A1 (en) * | 2020-04-01 | 2023-06-15 | Washington University | Compositions for treatment of viral respiratory infections and methods of use thereof |
| CN112626099A (zh) * | 2020-09-29 | 2021-04-09 | 清华大学 | 使用原核细胞发酵表达血管紧张素转化酶2的方法 |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
| US20250009853A1 (en) | 2021-12-03 | 2025-01-09 | Wisconsin Alumni Research Foundation | Mutant ace2 proteins and methods of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US6989363B1 (en) | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US6194556B1 (en) | 1997-12-11 | 2001-02-27 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor |
| EP1485116A4 (en) * | 2002-02-27 | 2006-06-07 | Univ Wake Forest | ANGIOTENSIN- (1-7) AND AGONISTS OF ANGIOTENSIN- (1-7) FOR THE INHIBITION OF GROWTH OF CANCER CELLS |
| SI2332582T1 (sl) * | 2002-06-19 | 2014-03-31 | Apeiron Biologics Ag | Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije |
| EP1374907A3 (en) | 2002-06-24 | 2004-01-07 | Ghanem Elias c/o Institut Jules Bordet Ghanem | Drug transport and delivery system |
| EP1723962A1 (en) * | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
-
2008
- 2008-04-09 AT AT0056608A patent/AT506632A1/de not_active Application Discontinuation
-
2009
- 2009-04-07 WO PCT/AT2009/000136 patent/WO2009124330A2/de not_active Ceased
- 2009-04-07 PT PT97307714T patent/PT2274005E/pt unknown
- 2009-04-07 ES ES09730771T patent/ES2425308T3/es active Active
- 2009-04-07 DK DK09730771.4T patent/DK2274005T3/da active
- 2009-04-07 PL PL09730771T patent/PL2274005T3/pl unknown
- 2009-04-07 EP EP13162709.3A patent/EP2644203A1/de not_active Withdrawn
- 2009-04-07 US US12/937,029 patent/US8946162B2/en active Active
- 2009-04-07 EP EP09730771.4A patent/EP2274005B1/de active Active
- 2009-04-07 JP JP2011503304A patent/JP5650639B2/ja active Active
- 2009-04-07 CA CA2720616A patent/CA2720616C/en active Active
- 2009-04-07 AU AU2009235931A patent/AU2009235931B2/en active Active
- 2009-04-07 NZ NZ588435A patent/NZ588435A/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mai et al. | Targeting legumain as a novel therapeutic strategy in cancers | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| BR112013029212A2 (pt) | anticorpos para o tratamento de câncer expressando claudina-6 | |
| NZ604973A (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| JP2013163674A5 (enExample) | ||
| NZ588435A (en) | Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer) | |
| BR112012011143A2 (pt) | "anticorpos específicos para claudina 6 (cldn6)". | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| JP2009102444A5 (ja) | 二次性骨腫瘍の治療のための抗PDGFRα抗体 | |
| JP2010209101A5 (enExample) | ||
| WO2011038142A3 (en) | Bladder cancer specific ligand peptides | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| Xu et al. | Recent advances in the treatment of colon cancer | |
| JP2021105005A5 (enExample) | ||
| WO2009067520A3 (en) | Peptides specific for hepatocellular carcinoma cells and applications thereof | |
| JP2016526021A5 (enExample) | ||
| WO2009124281A3 (en) | Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis | |
| JP2014510699A5 (enExample) | ||
| WO2005094348A3 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
| JP2015506352A5 (enExample) | ||
| WO2012009663A3 (en) | New compounds for treating cancer and other diseases | |
| Wang et al. | Matrix metalloproteinases (MMPs) in targeted drug delivery: synthesis of a potent and highly selective inhibitor against matrix metalloproteinase-7 | |
| WO2011051271A3 (en) | Prostate tumor markers and methods of use thereof | |
| CN105997978B (zh) | 一种金属有机骨架化合物抗肿瘤血管生成剂及其使用方法 | |
| JP2016500649A5 (enExample) |